Ultragenyx Pharmaceutical Inc. buy Bank of America Co.
Start price
31.05.24
/
50%
€37.00
Target price
31.05.25
€70.03
Performance (%)
-20.00%
End price
01.06.25
€29.60
Summary
This prediction ended on 01.06.25 with a price of €29.60. The price of Ultragenyx Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -20.00%. Bank_of_America_Co_ has a follow-up prediction for Ultragenyx Pharmaceutical Inc. where he still thinks Ultragenyx Pharmaceutical Inc. is a Buy. Bank_of_America_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.503% | -0.503% | -53.081% |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Bank of America Co. from $83.00 to $76.00. They now have a "buy" rating on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Bank_of_America_Co_ gewählte maximale Laufzeit wurde überschritten
Current prediction by Bank_of_America_Co_ for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€19.80
02.01.26
02.01.26
€49.31
02.01.27
02.01.27
-2.02%
09.01.26
09.01.26
